AXL is a promising novel therapeutic target in a variety of cancers, such as BC, acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), pancreatic cancer and prostate cancer [10, 23, 24, 26, 27]. This evidence concerns the gene AXL and prostate carcinoma.